AF

Afya Limited

AFYAConsumer DefensiveNASDAQ

Education & Training Services · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.70B
+11.9% YoY
Net Income
$752.5M
+19.2% YoY
EBITDA
$1.67B
+21.6% YoY
Free Cash Flow
$386.6M

Scan Results

Daily timeframe
1 recent day hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3CONFIRMED RSI OverboughtRSI 79.1, above 70, stock may be overbought
Aug 31CONFIRMED RSI OverboughtRSI 70.2, above 70, stock may be overbought
About Afya Limited

Afya Limited operates as a medical education group in Brazil. The $1.26B market capitalization puts AFYA squarely in small-cap range for its industry. The company operates in three segments: Undergraduate, Continuing Education, and Medical Practice Solutions.

Where AFYA stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, AFYA finished 4.78% above its 150-day moving average ($14.23) and 5.00% above its 200-day moving average ($14.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is AFYA overbought or oversold?

At the September 3, 2026 close, AFYA's RSI(14) was 79.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$1.26B
P/E (TTM)8.41
Fwd P/E7.17
EPS$1.70
Beta0.38
52W Change-5.7%
Dividend Yield4.48%
ROE16.7%
Analysis

The company holds $1.01B in cash, though total debt stands at $3.12B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $386.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 16.7%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.4% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.33B (2022) to $3.70B (2025), reflecting a 59% increase over the period.

With a beta below 0.7, Afya Limited typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing AFYA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.

Links
More Consumer Defensive stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms